The Stockholm3 model combines PSA, plasma protein biomarkers, polygenic risk, and clinical factors for prostate cancer screening.

Investigators proposed novel PSA thresholds for prostate cancer biochemical recurrence: PSA nadir plus 0.5 ng/mL after radiation therapy and PSA 0.5 ng/mL or higher with a PSA doubling time of 9 ...

About eight in 10 men will be diagnosed with prostate cancer in their lifetime. It’s the second leading cause of cancer death in men, behind only heart disease. About 1 in 8 men will be diagnosed with ...

A single PSA test at midlife may identify men with a low risk of prostate cancer for up to 20 years, supporting longer screening intervals. Men with a low baseline PSA level at midlife have a low risk ...